kenyboy, Amarin has a patent for hypertriglyceridemia which is (150-499 mg/dl) which was approved for CVE. Hikma received their approval for the SH severe hypertriglyceridemia (>500 mg/dl) and carved out the CVE (150-499). Your Opinion below states the opposite. "concluding that Hikma’s generic product—approved only for the treatment of hypertriglyceridemia" from the 1st paragraph below. AI got that wrong.
Market Data 
Markets 
AI
